Expression profiling of genes in rheumatoid fibroblast-like synoviocytes regulated by tumor necrosis factor-like ligand 1A using cDNA microarray analysis

KOJI FUKUDA1, YASUSHI MIURA1,2, TOSHIHISA MAEDA1, SHINYA HAYASHI1 and RYOSUKE KURODA1

1Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Hyogo 650-0017; 2Division of Orthopedic Science, Department of Rehabilitation Science, Kobe University Graduate School of Health Science, Kobe, Hyogo 654-0142, Japan

Received October 29, 2018; Accepted May 9, 2019

DOI: 10.3892/br.2019.1216

Abstract. Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation in synovial tissues. Hyperplasia of synovial tissue leads to the formation of pannus, which invades joint cartilage and bone resulting in joint destruction. Tumor necrosis factor-like ligand 1A (TL1A), a member of the tumor necrosis factor superfamily (TNFSF15), contributes to the pathogenesis of autoimmune diseases, including RA. In the present study, a cDNA microarray was used to search for genes whose expression in rheumatoid fibroblast-like synoviocytes (RA-FLS) were regulated by TL1A. Four individual lines of primary cultured RA-FLS were incubated either with recombinant human TL1A protein or phosphate-buffered saline, as an unstimulated control, for 12 h. Gene expression was then detected through the microarray assay. The results revealed the expression profiles of genes in RA-FLS regulated by TL1A. The present study also demonstrated the functions of those genes whose expression in RA-FLS was regulated by TL1A. Among the genes in this profile, the present study focused on the following genes: Spectrin repeat-containing nuclear envelope 1, Fc receptor-like 2, PYD (pyrin domain)-containing 1, cell division cycle 45 homolog, signal transducer and activator of transcription 5B, and interferon regulatory factor 4. These genes may affect the pathogenesis of RA, including proliferation, regulation of B cells and T cells, inflammation, and cytokine processing. The present study revealed for the first time, to the best of our knowledge, the expression profile of genes in RA-FLS regulated by TL1A. The data indicate that TL1A may regulate the gene expression of various key molecules in RA-FLS, thus affecting the pathogenesis of RA. Further investigations of the genes detected in the current profiles may provide a deeper understanding of the pathogenesis and a novel target for the treatment of RA.

Introduction

Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation in synovial tissues. Hyperplasia of synovial tissue leads to the formation of pannus, which invades joint cartilage and bone, resulting in joint destruction. Previous reports have indicated that a number of features of transformed long-lived cells are observed in the hyperplastic synovial tissues of patients with RA, including oncogene expression, resistance to apoptosis and the presence of somatic mutations (1-3). Several explanations for the resistance of RA-FLS to apoptosis have been suggested, including deregulation of the Bcl-2 family of proteins critical to intrinsic pathway regulation, deregulation of the nuclear factor (NF)-κB signaling pathway, p53 mutations and a low expression of PUMA, found in the RA synovium and FLS, which provides an explanation for the lack of p53-induced FLS apoptosis (4).

Tumor necrosis factor (TNF)-like ligand 1A (TL1A)/TNFSF15, a member of the TNF superfamily, is expressed by endothelial cells (5), macrophages (6,7), T cells (8,9), monocytes (10,11), dendritic cells (11), chondrocytes (12) and synovial fibroblasts (12), and contributes to the pathogenesis of cancer and autoimmune diseases via the apoptotic, stress, mitogenic and inflammation pathways by binding to death receptor 3 (DR3) and decoy receptor 3 (DcR3) (5,13). Previous studies have reported that the expression of TL1A is increased in the synovial fluid and serum from patients with RA (12,14), and that TL1A increases the production of interleukin (IL)-6 on rheumatoid fibroblast-like synoviocytes (RA-FLS) (15). In a previous in vivo study, it was demonstrated that TL1A treatment increased the severity of arthritis and destruction of bone in a collagen-induced arthritis mouse model of RA (12).

DcR3/TR6/M68/TNFRSF6b, a member of the TNF receptor superfamily, binds to three ligands, Fas ligand
(FasL), LIGHT and TL1A, which are members of the TNF superfamily (16). The overexpression of DcR3 may benefit tumors by enabling them to avoid the cytotoxic and regulatory effects of FasL (17,18), LIGHT (19) and TL1A (5). In our previous studies, it was demonstrated that DcR3 is expressed in RA-FLS (20), and that DcR3 binds to TL1A expressed on RA-FLS, resulting in the negative regulation of cell proliferation induced by inflammatory cytokines (21). The expression profiles of genes regulated by DcR3 in RA-FLS were further revealed, which were obtained through the use of a cDNA microarray (22). Based on these profiles, it was suggested that DcR3-TL1A signaling is involved in the pathogenesis of RA (23-25).

Although the gene expression profiles regulated by DcR3 were revealed in our previous study, how TL1A, one of the ligands of DcR3, contributes to the pathogenesis of RA remains to be fully elucidated. As the functions of TL1A are diverse, it was hypothesized that TL1A controls the expression of genes potentially involved in the pathogenesis of RA.

In the present study, a search was performed to identify those genes whose expression in RA-FLS is regulated by TL1A through use of a cDNA microarray. The gene expression profiles revealed a series of genes that may serve a significant role in the pathogenesis of RA in the TL1A-DcR3/DR3 signaling pathway.

Materials and methods

Isolation and culture of synovial fibroblasts. RA-FLS were obtained from four patients (samples 1-4) with RA who fulfilled the 1987 criteria of the American College of Rheumatology (formerly, the American Rheumatism Association) (26) during total knee replacement surgery. The patients were four women aged 73.0±11.2 years old. Their C-reactive protein levels and erythrocyte sedimentation rates were 2.04±2.16 mg/dl and 60.0±22.1 mm/h, respectively. In terms of drug therapy for RA, two patients were administered oral methotrexate (MTX; average dose, 3.00±1.41 mg/week), one was administered salazosulfapyridine (1 g/day), and one was administered mizoribine (150 mg/day). Prednisolone (PSL) was used in the treatment of all four patients (average dose, 3.63±2.14 mg/day). The patients had never been treated with biological disease-modifying anti-rheumatic drugs or Janus kinase inhibitors.

Synovial samples were collected from the patients, who provided informed written consent to their involvement in the study in accordance with the World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects. The protocol, including consent procedures, was approved by the Ethics Committee of Kobe University Graduate School of Health Sciences (Kobe, Japan; approval no. 308). The tissue specimens were minced and digested in Dulbecco’s modified Eagle’s medium (DMEM; Merck KGaA, Darmstadt, Germany) containing 0.2% collagenase (Merck KGaA) for 2 h at 37˚C with 5% CO₂. The dissociated cells were cultured in DMEM supplemented with 10% fetal bovine serum (Merck KGaA) and 100 U/ml of penicillin/streptomycin (Meiji Seika Pharma Co., Ltd., Tokyo, Japan). Following incubation overnight and the removal of non-adherent cells, the adherent cells were further incubated in fresh medium. All experiments were performed using cells from passages 3-4 (20).

RNA extraction. Four individual cell lines (samples 1-4) of primary cultured RA-FLS (2x10⁶ cells/well) were incubated with 1.0 µg/ml of recombinant human TL1A protein (R&D Systems, Inc., Minneapolis, MN, USA) or were left untreated with OPTI-MEM medium (Thermo Fisher Scientific, Inc., Waltham, MA, USA) for 12 h at 37˚C with 5% CO₂. Following incubation, RNA was extracted with QIAshredder (Qiagen GmbH, Hilden, Germany) and RNeasy Mini kit (Qiagen GmbH) according to the manufacturer’s protocol. The extraction of total RNA was performed for each sample separately.

Gene expression profiling and data analysis. Gene expression was detected by microarray assay (Human Genome U133 Plus 2.0, GeneChip® 3’ Expression Array; Thermo Fisher Scientific, Inc.). The labeling of RNA probes, hybridization and washing were performed according to the manufacturer's protocol.

Avadis 3.3 Prophetic software (Strand Life Sciences, Bangalore, India) was used for statistical analysis (27). Differentially expressed genes were extracted using a paired t-test with P<0.05 considered to indicate a statistically significant difference and fold-change >1.4, and ordered into hierarchical clusters using the Euclidean algorithm as the distance measure and the complete algorithm as the linkage method. Values are expressed as the mean ± standard deviation unless otherwise indicated.

Results

Microarray analysis for gene expression profiling of RA-FLS stimulated by TL1A. The microarray analysis performed in the present study (Human Genome U133 Plus 2.0, GeneChip® 3’ Expression Array) detected the expression of 54,613 genes. The entire microarray data obtained were deposited in the NCBI Gene Expression Omnibus (GEO) and are accessible through GEO series accession no. GSE118958 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=gse118958).

The microarray analysis revealed that TL1A upregulated or downregulated the expression of various genes in RA-FLS. The NCBI UniGene database (https://www.ncbi.nlm.nih.gov/UniGene/clust.cgi?ORG=Hs&CID=55682) was used to identify the gene names, with gene symbols representing abbreviations of the gene names. The fold change is the ratio of each gene expression in the TL1A-stimulated group compared with that in the control group. Among the 100 most differentially upregulated genes by TL1A, 67 genes were annotated in the database, and 21 of these 67 genes upregulated by TL1A are shown in Table I. Gene annotations of 58 of the 100 most differentially downregulated genes by TL1A were also annotated in the database, and 21 of the 58 genes downregulated by TL1A are shown in Table II. The results of hierarchical clustering analysis for the 100 most upregulated genes and the 100 most downregulated genes are illustrated in Figs. 1 and 2, respectively.

Functional annotation. The 100 genes most regulated by TL1A were significantly classified into 14 categories registered in the Database for Annotation, Visualization and Integrated
Table I. List of the 21 genes upregulated by tumor necrosis factor-like ligand 1A.

| Gene symbol | Fold-change | P-value     | Gene name                                                                 |
|-------------|-------------|-------------|---------------------------------------------------------------------------|
| SYNE1       | 15.3        | 0.013391    | Spectrin-repeat-containing, nuclear envelope 1                             |
| PDE11A      | 14.40000186 | 0.013724    | Phosphodiesterase 11A                                                     |
| MGC15705    | 12.6299996  | 0.006738    | Hypothetical protein MGC15705                                             |
| COG2        | 12.61445783 | 0.016001    | Component of oligomeric golgi complex 2                                   |
| FCR2        | 11.97633136 | 0.000003    | Fc receptor-like 2                                                         |
| RAD21L1     | 11.82758621 | 0.007302    | RAD21-like 1 (S. pombe)                                                   |
| PPF4R1L     | 10.1975316  | 0.005913    | Protein phosphatase 4, regulatory subunit 1-like                           |
| MIER3       | 9.72072035  | 0.048129    | Mesoderm induction early response 1, family member 3                       |
| LOC100505801| 9.711538484 | 0.029304    | Hypothetical LOC100505801                                                 |
| C12orf74    | 9.576924282 | 0.008377    | Chromosome 12 open reading frame 74                                       |
| CCNE2       | 9.118012422 | 0.039656    | Cyclin E2                                                                 |
| LOC100288507| 9.064056744 | 0.009929    | Hypothetical protein LOC100288507                                         |
| USH2A       | 8.986842105 | 0.048673    | Usher syndrome 2A (autosomal recessive, mild)                              |
| SEZ6L       | 8.7578125   | 0.002512    | Seizure related 6 homolog (mouse)-like                                     |
| LOC100133308| 8.376812174 | 0.026850    | Ras suppressor protein 1 pseudogene                                       |
| MLL         | 8.3571295   | 0.007109    | Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila) |
| SYTL3       | 8.348148148 | 0.038552    | Synaptotagmin-like 3                                                      |
| GAGE12F///GAGE12G/// | 8.124137931 | 0.018128 | G antigen 12F///G antigen 12G///G antigen 12I///G antigen 5/// |
| GAGE12I///GAGE5///GAGE7   | 8.891089109 | 0.044768 | FERM domain-containing 4A                                                |
| LOC404266   | 7.725807116 | 0.003327    | Hypothetical LOC404266                                                   |
| PYDC1       | 5.42662116  | 0.006955    | PYD (pyrin domain)-containing 1                                           |

Table II. List of the 21 genes downregulated by tumor necrosis factor-like ligand 1A.

| Gene symbol | Fold-change | P-value     | Gene name                                                                 |
|-------------|-------------|-------------|---------------------------------------------------------------------------|
| CDC45       | 0.08        | 0.006927    | Cell division cycle 45 homolog (S. cerevisiae)                            |
| STAT5B      | 0.10        | 0.019873    | Signal transducer and activator of transcription 5B                       |
| BEND4       | 0.11        | 0.026734    | BEN domain-containing 4                                                   |
| ALAS2       | 0.11        | 0.004251    | Aminolevulinate, δ-, synthase 2                                           |
| LOC728743   | 0.11        | 0.031562    | Similar to GLI-Kruppel family member HKR1                                  |
| LOC100130815| 0.12        | 0.037456    | Hypothetical LOC100130815                                                |
| LOC255130   | 0.12        | 0.020509    | Hypothetical LOC255130                                                   |
| RBM25       | 0.12        | 0.032102    | RNA-binding motif protein 25                                              |
| PARP15      | 0.12        | 0.028280    | Poly (ADP-ribose) polymerase family, member 15                            |
| SUFU        | 0.12        | 0.025031    | Suppressor of fused homolog (Drosophila)                                  |
| MUC7        | 0.12        | 0.045462    | Mucin 7, secreted                                                         |
| VPS35       | 0.12        | 0.013976    | Vacuolar protein sorting 35 homolog (S. cerevisiae)                       |
| GKN1        | 0.13        | 0.013159    | Gastrokine 1                                                              |
| KRT77       | 0.13        | 0.030364    | Keratin 7                                                                 |
| GOT1L1      | 0.14        | 0.047977    | Glutamic-oxaloacetic transaminase 1-like 1                                |
| DEFA5       | 0.14        | 0.005483    | Defensin, α5, Paneth cell-specific                                         |
| SLC13A3     | 0.14        | 0.041769    | Solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 3 |
| C10orf137   | 0.15        | 0.030915    | Chromosome 10 open reading frame 137                                       |
| PRTN3       | 0.15        | 0.001312    | Proteinase 3                                                              |
| RASGGRP1    | 0.15        | 0.038526    | RAS guanyl-releasing protein 1 (calcium and DAG-regulated)                 |
| IRF4        | 0.22        | 0.027305    | Interferon regulatory factor 4                                            |
Figure 1. Cluster analysis and heat map of 100 probe sets significantly upregulated by TL1A. The heat map shows expression values mapped to a color gradient from low (green) to high expression (red). Experiments are arranged according to a hierarchical clustering dendrogram. The horizontal dendrogram shows the similarity of functions between neighboring genes. The vertical dendrogram shows the similarity of gene expression between neighboring samples. TL1A, tumor necrosis factor-like ligand 1A; CTL, control.

Figure 2. Cluster analysis and heat map of 100 probe sets significantly downregulated by TL1A. The heat map shows expression values mapped to a color gradient from low (green) to high expression (red). Experiments are arranged according to a hierarchical clustering dendrogram. The horizontal dendrogram shows the similarity of functions between neighboring genes. The vertical dendrogram shows the similarity of gene expression between neighboring samples. TL1A, tumor necrosis factor-like ligand 1A; CTL, control.

Discovery bioinformatics database (https://david.ncifcrf.gov/) according to their biological functions; alternative splicing, splice variant, coenzyme A, regulation of cytokine production, Cyclin; N-terminal, Cyclin, Pleckstrin homology-type, CYCLIN, transcription from RNA polymerase II promoter, cyclin, compositionally biased region: Ser-rich, postsynaptic
membrane, positive regulation of transcription from RNA polymerase II promoter, and synapse. The regulated genes belonging to each cluster are listed in Table III.

**Discussion**

Genome-wide gene expression cDNA microarrays provide a useful way of investigating the pathophysiology of a variety of diseases, including tumors (28-30), immune-mediated diseases (31,32), and inflammatory diseases (33-35). Using microarrays, our previous study revealed the expression profiles of genes in RA-FLS regulated by DcR3 (22). Subsequently, based on that profile, the significance of the regulation of IL-12B p40 (23), tryptophan hydroxylase 1 (24), and centrosomal protein 70 kDa (25) by DcR3 in RA-FLS was investigated in detail.

The present study is the first, to the best of our knowledge, to demonstrate the expression profiles of genes in RA-FLS regulated by TL1A. Among the genes in this profile, the following genes were of note: Spectrin repeat-containing nuclear envelope 1 (SYNE1), Fc receptor-like 2 (FCRL2), PYD (pyrin domain)-containing 1 (PYDC1), cell division cycle 45 homolog (CDC45), signal transducer and activator of transcription 5B (STAT5B), and interferon regulatory factor 4 (IRF4), as these genes were highly regulated by TL1A and belong to major functional clustering categories.

SYNE1 in RA-FLS was upregulated by TL1A in this gene expression profile. SYNE1 is a member of the spectrin family that is expressed in various tissues (36,37). It is reported to be associated with cytokinesis in HeLa cells (38), and the proliferation and apoptosis of mesenchymal stem cells (39).

FCRL2 was upregulated in this profile and is a member of the Fc receptor-like molecules superfamily. It is predominantly expressed by memory B cells and can influence B-cell signaling due to having both immunoreceptor tyrosine-based activation and inhibitory motifs (40-42). Jackson et al suggested that FCRL2 may serve as a negative regulator of the memory B cell response (43). FCRL2 has been reported to be expressed at high levels in B-cell chronic lymphocytic leukemia cells, affecting...
disease progression and survival rates (42,44,45), and is associated with the inflammatory marker and disease activity of RA (46).

PYDC1 was upregulated in this profile. PYD-containing proteins have been reported to be involved in the activation of NF-κB and caspase-1, which regulates the processing of IL-1β and IL-18, and is associated with inflammation and apoptosis (47-49).

CDC45 was downregulated in this profile. CDC45 serves a critical role in DNA replication (50), and has been reported to be overexpressed in cancer cells (51) and cancer-derived cell lines (52). The expression of CDC45 is significantly suppressed by the knockdown of IL-1 receptor-associated kinase 1 in endometrial carcinoma (53). The expression of CDC45 is closely associated with proliferating cell populations in cancer (52).

STAT5B was downregulated in this profile. STATs regulate gene transcription to influence cellular functions, including proliferation, apoptosis, differentiation, reproduction and lipid metabolism, and have biological roles in several diseases, including autoimmune disease (54-60). The expression and activity of STATs can contribute to the onset, progression and severity of RA (61).

IRF4 was downregulated in this profile. IRF4 has been reported to be an RA risk locus, as identified by GWAS data analysis (62). IRF4 is an IRF family member of transcription factors and is associated with the development and function of immune cells (63). Previous studies have found that IRF4 regulates autoimmunity (63,64). In addition, IRF4 regulates Th17 cell differentiation and the production of IL-17, which are important for modulation of autoimmunity, including RA (63,65).

Although neither SYNE1 nor CDC45 are reported to be associated with RA directly, SYNE1 is associated with cytokinesis, proliferation and apoptosis, and CDC45 serves a critical role in the cell cycle of proliferating cells, which are important factors in the pathogenesis of RA.

The limitations of the present study included its small sample size and that it examined microarray data only, without detecting mRNA or protein expression. The results of the present study revealed a series of genes whose expression is regulated by TL1A in RA-FLS using microarray analysis, however, each gene revealed through microarray analysis requires confirmation one by one with mRNA or protein analysis in a future study. In addition to the expression analysis of each genes, how these genes regulated by TL1A in RA-FLS are involved in combination in the pathogenesis of RA also requires investigation in a future study.

In conclusion, the present study is the first, to the best of our knowledge, to report the expression profile of genes in RA-FLS regulated by TL1A. The data demonstrate that TL1A may regulate the gene expression of various key molecules in RA-FLS, thus affecting the pathogenesis of RA, including proliferation, regulation of B cells and T cells, inflammation, and cytokine processing. Further investigations of the genes detected in this profile may provide a deeper understanding of the pathogenesis and novel targets for the treatment of RA.

Acknowledgements

The authors would like to thank Mrs. Kyoko Tanaka, Ms. Minako Nagata and Ms. Maya Yasuda (Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan) for their technical assistance.

Funding

This study was supported by a Grant-in-Aid for Scientific Research (KAKENHI; grant nos. 15K10473 and 18K09106).

Availability of data and materials

The datasets generated and analyzed during the current study are available in the NCBI GEO repository and are accessible through GEO series accession no. GSE118958, (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=gse118958).

Authors' contributions

KF was involved in conception and design, data collection and analysis, manuscript writing and final approval of the manuscript; YM was involved in conception and design, data collection and analysis, manuscript writing and final approval of the manuscript. TM was involved in conception and design, data collection, and final approval of the manuscript. SH was involved in conception and design, data collection and final approval of the manuscript. RK was involved in conception and design, data collection, and final approval of the manuscript.

Ethics approval and consent to participate

The study protocol, including consent procedures, was approved by the Ethics Committee of Kobe University Graduate School of Health Sciences (approval no. 308).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Chou CT, Yang JS and Lee MR: Apoptosis in rheumatoid arthritis-expression of Fas, Fas-L, p53, and Bcl-2 in rheumatoid synovial tissues. J Pathol 193: 110-116, 2001.
2. Tak PP, Zvaifler NJ, Green DR and Firestein GS: Rheumatoid arthritis and p53: How oxidative stress might alter the course of inflammatory diseases. Immunol Today 21: 78-82, 2000.
3. Yamanishi Y, Boyle DL, Rosengren S, Green DR, Zvaifler NJ and Firestein GS: Regional analysis of p53 mutations in rheumatoid arthritis synovium. Proc Natl Acad Sci USA 99: 10025-10030, 2002.
4. Bustamante MF, Garcia-Carbonell R, Whisenant KD and Guma M: Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther 19: 110, 2017.
5. Migone TS, Zhang J, Luo X, Zhuang L, Chen C, Hu B, Hong JS, Perry JW, Chen SF, Zhou JX, et al: TL1A is a TNF-like ligand for DR3 and TR6/Dr3 and functions as a T cell costimulator. Immunity 16: 479-492, 2002.
6. Kamada N, Hisamatsu T, Honda H, Kobayashi T, Chinen H, Takayama T, Kitazume MT, Okamoto S, Koganei K, Sugita A, et al: TL1A produced by lamina propria macrophages induces Th1 and Th17 immune responses in cooperation with IL-23 in patients with Crohn's disease. Inflamm Bowel Dis 16: 568-575, 2010.
7. Bamias G, Martin C III, Marini M, Hoang S, Mishina M, Ross WG, Sachedina MA, Fried CM, Mize J, Bickston SJ, et al.: Expression, localization, and functional activity of TL1A, a novel pro-caspase-1 regulation. Biochem J 373: 101-118, 2003.
8. Prehn JL, Mehdizadeh S, Landers CJ, Lu X, Cha SC, Wei P and Targan SR: Potential role for TL1A, the new TNF-family member and potent costimulator of IFN-gamma, in mucosal inflammation. Clin Immunol 112: 67-77, 2004.
9. Papadakis P, Stathopoulou D, Prehn HL, Landers C, Avanesyan A, Lafkas G and Targan SR: Dominant role for TL1A/DR3 pathway in IL-12 plus IL-18-induced IFN-gamma production by peripheral blood and mucosal CCR9+ T lymphocytes. J Immunol 174: 4985-4995, 2005.
10. Cassatella MA, Pereira-da-Silva G, Tinazzi I, Facchetti F, Scapini P, Formigli L and Tamussino N: Wei P, Nardelli B, Boschke V, et al: Soluble TNF-like cytokine (TL1A) production by immune complexes stimulates monocytes in rheumatoid arthritis. J Immunol 178: 7325-7333, 2007.
11. Prehn JL, Thomas LS, Landers CJ, Yu QT, Michelsen KS and Targan SR: The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells. J Immunol 178: 4033-4038, 2007.
12. Zhang J, Wang X, Fahmi H, Wojcik S, Fikes J, Yu Y, Wu J and Luo H: Role of TL1A in the pathogenesis of rheumatoid arthritis. J Immunol 183: 80-85, 2009.
13. Sethi G, Miao B and Agerwaal BB: Therapeutic potential of VEGF/TL1A in autoimmunity and cancer. Adv Exp Med Biol 647: 207-215, 2009.
14. Bamias G, Stakavellas SL, Stamatopoulou KS, Chryssochou E, Papamichael C and Silikas PP: Circulating levels of TNF-like cytokines and their decoy receptors in rheumatoid arthritis. Cytokine 83: 92-98, 2016.
15. Endogenous decoy receptor 3 blocks the growth inhibition by preferentially activating TNF receptor 2 in rheumatoid arthritis. Cytokine 83: 92-98, 2016.
16. Shi G, Wu Y, Zhang J and Wu J: Death receptor decoy TR6/Dr3 inhibits T cell chemotaxis in vitro and in vivo. J Immunol 171: 3407-3414, 2003.
17. Pitti RM, Marsters SA, Lawrence SA, Roy M, Kischkel FC, Dowd P, Huang A, Domahc JE, Sherwood BW, Baldwin DT, et al: Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396: 699-703, 1998.
18. Tsuji S, Hosotani R, Yonchara S, Masui T, Tulachan SS, Nakajima K, Kobayashi H, Koizumi M, Toyoda E, Ito O, et al: Endogenous decoy receptor 3 blocks the growth inhibition signals mediated by Fas ligand in human adenocarcinoma. Int J Cancer 106: 17-25, 2003.
19. Yu KY, Kwon B, Ni J, Zhai Y, Ebner R and Kwon BS: A newly identified member of tumor necrosis factor receptor superfamily plays an important role in the proliferation and apoptosis of mesenchymal stem cells. Int J Mol Med 32: 805-812, 2013.
20. Davis RS: Fc receptor-like molecules. Annu Rev Immunol 25: 525-560, 2007.
21. Shabani M, Bayat AA, Jeddi-Tehrani M, Rabhani H, Hojati-Farsangi M, Ulivieri C, Amirghofran Z, Balardi CT and Shokri F: Ligation of human Fc receptor like-2 by monoclonal antibodies down-regulates B-cell receptor-mediated signalling. Immunology 143: 341-353, 2014.
22. Nuckel H, Collins CH, Frey UH, Sellmann L, Dürrig J, Sifffert W and Dührsen U: FCRL2 mRNA expression is inversely associated with clinical progression in chronic lymphocytic leukemia. Eur J Haematol 83: 541-549, 2009.
23. Jackson TA, Haga CL, Ehrhardt GR, Davis RS and Cooper MD: FcεR-like 2 Inhibition of B cell receptor-mediated activation of B cells. J Immunol 185: 7405-7412, 2010.
24. Li FY, Ding S, Pan J, Shakhbut MOV, Kashenteva E, Wu J, Li Y, Soong SJ, Chiorazzi N and Davis RS: FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia. Blood 112: 179-187, 2008.
25. Stamatopoulos B, Haibe-Kains B, Equeurt C, Meuleman N, Sorlie A, De Bruyne C, Honesset A, Bron D, Martiat P and Lageaux L: Gene expression profiling reveals differences in the microenvironment interaction between patients with chronic lymphocytic leukemia expressing high versus low ZAP70 mRNA. Haematologica 94: 790-799, 2009.
26. Biddison WE: Analysis of gene expression in multiple sclerosis lesions using cDNA microarrays. Adv Immunol 50: 315-324, 1994.
27. Choi YJ and Yun HK: Transcriptional profiles of Rhizobium vitis-inoculated and salicylic acid-treated 'Tamnara' grapevines based on microarray analysis. J Plant Biotechnol 43: 34-48, 2016.
28. Chang YC, Chen TC, Lee YT, Yang CL, Wang HH, Wang CC and Hsieh SL: Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3. Blood 111: 5054-5063, 2008.
29. Espinosa I, Catasus L, Canet B, D'Angelo E, Muñoz J and Prat J: Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis. Mod Pathol 24: 846-854, 2011.
30. Khan J, Simon R, Bittner M, Chen Y, Leighton SB, Pohida T, Smith PD, Jiang Y, Gooden GC, Trent JM and Meltzer PS: Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res 59: 5009-5017, 1999.
31. Whitney LW, Becker KG, Tresser NJ, Caballero-Ramos Cl, Munson PJ, Prabhu VV, Trent JM, McFarland HF and Biddison WE: Analysis of gene expression in multiple sclerosis lesions using cDNA microarrays. Ann Neurol 46: 425-428, 1999.
32. Li Y, Yang S, Lu S, Zhua H, Feng J, Li W, Ma F, Ren Q, Liu B, Zhang L, et al: Differential gene expression profile associated with the abnormality of bone marrow mesenchymal stem cells in aplastic anemia. PLoS One 7: e47764, 2012.
33. van der Pouw Kraan TC, van Gaalen FA, Kasperskovi PV, Verbeet NL, Smets T, Kraan MC, Fero M, Tak PP, Huizinga TW, Pietteard E, et al: Decoy receptor 3 expressed in rheumatoid arthritis is an essential molecule for heterogeneous disease: Evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues. Arthritis Rheum 48: 2132-2145, 2003.
34. Lee SK, Jeon EK, Kim YJ, Seo SH, Kim CD, Lim JS and Lee JH: A global gene expression analysis of the peripheral blood mononuclear cells reveals the gene expression signature in psoriasis. Ann Dermatol 21: 237-242, 2009.
35. Heller RA, Schena M, Chai A, Shalon D, Bedilion T, Gilmore J, Woolley DE and Davis KW: Discovery and analysis of inflammatory disease-related genes using cDNA microarrays. Proc Natl Acad Sci USA 94: 2150-2155, 1997.
36. Gough LL, Fan J, Chu S, Winnick S and Beck KA: Golgi localization of Syne-1. Mol Biol Cell 14: 2410-2420, 2003.
37. Apel ED, Lewis RM, Grady RM and Sames JR: Syne-1, a dystrophin- and Klastriah-related protein associated with synaptic nuclei at the neuromuscular junction. J Biol Chem 275: 31986-31995, 2000.
38. Prehn JL, Thomas LS, Landers CJ, Yu QT, Michelsen KS and Targan SR: The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells. J Immunol 178: 4033-4038, 2007.
39. Zhang J, Wang X, Fahmi H, Wojcik S, Fikes J, Yu Y, Wu J and Luo H: Role of TL1A in the pathogenesis of rheumatoid arthritis. J Immunol 183: 80-85, 2009.
40. Sethi G, Miao B and Agerwaal BB: Therapeutic potential of VEGF/TL1A in autoimmunity and cancer. Adv Exp Med Biol 647: 207-215, 2009.
41. Johnsson BI: Analysis of gene expression in mutiple sclerosis lesions using cDNA microarrays. Adv Immunol 50: 315-324, 1994.
42. Choi YJ and Yun HK: Transcriptional profiles of Rhizobium vitis-inoculated and salicylic acid-treated 'Tamnara' grapevines based on microarray analysis. J Plant Biotechnol 43: 34-48, 2016.
43. Chang YC, Chen TC, Lee YT, Yang CL, Wang HH, Wang CC and Hsieh SL: Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3. Blood 111: 5054-5063, 2008.
Stehlik C: The PYRIN domain in signal transduction. Curr Protein Pept Sci 8: 293-310, 2007.

49. Martinon F and Tschopp J: Inflammatory caspases: Linking an intracellular innate immune system to autoinflammatory diseases. Cell 117: 561-574, 2004.

50. Hopwood B and Dalton S: Cdc45p assembles into a complex with Cdc46p/Mcm5p, is required for minichromosome maintenance, and is essential for chromosomal DNA replication. Proc Natl Acad Sci USA 93: 12309-12314, 1996.

51. Sun J, Shi R, Zhao S, Li X, Lu S, Bu H and Ma X: Cell division cycle 45 promotes papillary thyroid cancer progression via regulating cell cycle. Tumour Biol 39: 1010428317705342, 2017.

52. Pollok S, Bauerschmidt C, Sänger J, Nasheuer HP and Grosse F: Human Cdc45 is a proliferation-associated antigen. FEBS J 274: 3669-3684, 2007.

53. Wang Y, Duan X and Zhang Z: Interleukin-1 receptor-associated kinase 1 correlates with metastasis and invasion in endometrial carcinoma. J Cell Biochem 119: 2545-2555, 2018.

54. Majri SS, Fritz JM, Villarino AV, Zheng L, Kanellopoulou C, Chaigne-Delalande B, Grönholm J, Niemela JE, Afzali B, Biancalana M, et al: STAT5b: A differential regulator of the life and death of CD4+ effector memory T cells. J Immunol 200: 110-118, 2018.

55. Darnell JE Jr: STATs and gene regulation. Science 277: 1630-1635, 1997.

56. O'Shea JJ, Lahesmaa R, Vahedi G, Laurence A and Kanno Y: Genomic views of STAT function in CD4+ T helper cell differentiation. Nat Rev Immunol 11: 239-250, 2011.

57. Villarino AV, Kanno Y, Ferdinand JR and O'Shea JJ: Mechanisms of Jak/STAT signaling in immunity and disease. J Immunol 194: 21-27, 2015.

58. Grimley PM, Dong F and Rui H: Stat5a and Stat5b: Fraternal twins of signal transduction and transcriptional activation. Cytokine Growth Factor Rev 10: 131-157, 1999.